For employers navigating rising healthcare costs, chronic kidney disease (CKD) represents one of the most significant — and preventable — drivers of long-term medical and pharmacy spend. The risk is especially pronounced among employees living with type 2 diabetes (T2D), where kidney damage often develops silently and escalates costs quickly once it advances.
Up to 40% of people with T2D will develop CKD , and diabetes remains the leading cause of kidney failure. Yet despite its prevalence, CKD is frequently detected too late — after opportunities to prevent progression, avoid medication-related harm, and manage costs more effectively have already passed.
National Kidney Month is a timely reminder that reducing the total cost of kidney disease doesn’t start with dialysis — it starts earlier, with prevention, connected care, and smarter medication management.
Early identification of CKD is a start to better outcomes
CKD is often called a “silent” condition for a reason. As many as 9 in 10 adults with CKD don't know they have it , according to the CDC. By the time symptoms appear, kidney damage is typically permanent, and care shifts from prevention to long-term management.
Employees with both T2D and CKD are three times more likely to die from a heart attack or stroke than those with diabetes alone. These outcomes drive higher medical costs, as well as rising pharmacy spend as treatment becomes more complex.
From an employer perspective, late detection locks organizations into a higher-cost trajectory. CKD acts as a disease multiplier , increasing the likelihood of cardiovascular events, hospitalizations, disability claims, and productivity loss.
The good news: early kidney damage is detectable well before symptoms appear using two low-cost, widely available tests — urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR).
As plan sponsors champion UACR and eGFR testing, it’s important to recognize that early identification is only the starting point. Closing care gaps beyond screening is essential to improving CKD outcomes.
Proactive, pharmacy-led prevention matters to the cost of care
Once risk is identified, pharmacy care plays a critical role in slowing CKD progression and avoiding preventable complications.
Many commonly used medications require adjustment as kidney function declines, and inappropriate dosing can lead to adverse events, hospitalizations, or accelerated disease progression.
A connected pharmacy approach helps ensure:
- Medications are appropriately dosed for kidney function.
- Nephrotoxic drugs are avoided when safer alternatives exist.
- Diabetes, blood pressure, and cardiovascular conditions are managed cohesively, not in silos.
- Newer therapies that protect kidney function are used appropriately and affordably.
This kind of proactive medication management doesn’t just support better clinical outcomes — it helps prevent costly downstream events like emergency care, inpatient admissions, and early progression to dialysis.
A whole-person approach to health that benefits the workforce
For employers and plan sponsors, the opportunity lies in shifting from reactive care to earlier, more coordinated pharmacy-led intervention. When kidney risk is identified early and paired with ongoing medication optimization, organizations can bend the cost curve while improving the member experience.
The potential effects are meaningful:
- Fewer high-cost claims tied to advanced kidney disease.
- Lower risk of cardiovascular events and hospitalizations.
- Improved adherence and medication safety.
- Better quality of life for employees managing chronic conditions.
Ultimately, reducing the total cost of kidney disease isn’t about a single test or intervention. It’s about connecting early detection with sustained pharmacy care — supporting whole-health outcomes while protecting affordability for employers and the people they serve.
You may also be interested in:
Weight management and whole health
From pipeline to prescription: the formulary development process at CarelonRx